||Salk type (IPV)
||Sabin type (OPV)
||Stands for inactivated polio vaccine.
||Stands for oral polio vaccine.
||Virus used is killed and formalized.
||Virus used is live and attenuated.
||Administered subcutaneously or intra muscularly.
||Good systemic immunity whereas mucosal slight or moderate.
||Good systemic immunity whereas excellent mucosal.
||Reversal of virulence through mutations not known.
||Reversal of virulence may be possible.
||Enteric viruses do not interfere the efficiency of vaccine.
||Enteric viruses may interfere its efficiency.
||Vaccine associated disease complication is not known.
||Vaccine associated disease complication may be possible.
||Vaccine administration is allowed to immune-compromised host.
||Vaccine administration is not allowed or recommended to immune-compromised host.
||High in manufacturing cost.
||Low in manufacturing cost.
||Jonas Salk developed this vaccine in 1954.
||Albert Sabin developed this vaccine in 1961.
||Long term immunity provided.
||Longer time immunity provided than Salk.
||Paralysis associated with the vaccine not observed.
||Paralysis associated with the vaccine is observed in very few cases.
||Antibody developed on the body is IgG.
||Antibodies developed in the body are IgG and IgA.
||Storage and transport does not require stringent conditions. Shelf life is longer.
||Storage and transportation needs sub-zero temperatures, unless stabilized. Can be damaged easily.
||Manufacturing is difficult.
||Manufacturing is easy.
||Controlling epidemics may not be possible.
||Can be more effective in controlling epidemics.
||Mostly used in developed countries.
||Mostly used in developing countries.
Image source: mcqbiology
Differences between Salk type (IPV) and Sabin type (OPV) vaccine